Nkarta
NKTX
About: Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Employees: 157
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
4.43% less ownership
Funds ownership: 86.72% [Q1] → 82.29% (-4.43%) [Q2]
6% less funds holding
Funds holding: 111 [Q1] → 104 (-7) [Q2]
14% less capital invested
Capital invested by funds: $113M [Q1] → $96.9M (-$16.3M) [Q2]
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
76% less call options, than puts
Call options by funds: $34K | Put options by funds: $142K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Stifel
Stephen Willey
|
$12
|
Buy
Maintained
|
14 Aug 2025 |
|
Needham
Gil Blum
|
$10
|
Buy
Reiterated
|
13 Aug 2025 |
Financial journalist opinion
